Company news

Swedish Orphan Biovitrum AB news in 2026

Swedish Orphan Biovitrum AB's news releases, calls and decks from 2026, newest first.

View company

Börje Ekholm is proposed as new Chair of the Sobi Board of Directors

October 29, 2026

Swedish Orphan Biovitrum: Sobi receives positive CHMP opinion for TRYNGOLZA (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

October 16, 2026

Invitation: Sobi's Q3 2026 report

October 8, 2026

Change in number of shares and votes in Sobi

September 30, 2026

Sobi and Innate announce partnership is now effective following completion of closing conditions

September 16, 2026

Swedish Orphan Biovitrum: Sobi and Innate announce partnership is now effective following completion of closing conditions

September 16, 2026

Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome

September 9, 2026

Sobi has completed an issue of class C shares

August 31, 2026

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

August 10, 2026

Guido Oelkers to step down as CEO of Sobi in the beginning of 2027

August 3, 2026

Sobi Q2 2026 report: Significant growth with important pipeline progress

July 16, 2026

The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under an incentive programme

July 15, 2026

Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

July 9, 2026

Invitation: Sobi's Q2 2026 report

July 1, 2026

Sobi to showcase new data across haemophilia portfolio at ISTH 2026

June 30, 2026

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

June 26, 2026

Sobi to present new clinical and real-world data at EHA 2026 in Stockholm

June 11, 2026

Sobi to present new data on pegcetacoplan at ERA 2026

June 1, 2026

Sobi to present new data on pegcetacoplan at ERA 2026

June 1, 2026

New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia

May 26, 2026

Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

May 21, 2026

Bulletin from Sobi's Annual General Meeting (AGM)

May 6, 2026

Sobi Q1 2026 report: Strong execution and pipeline momentum

April 28, 2026

Invitation: Sobi's Q1 2026 report

April 14, 2026

Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

April 9, 2026

Sobi publishes Annual and Sustainability Report for 2025

March 31, 2026

EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

March 30, 2026

Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)

March 27, 2026

Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM

March 18, 2026

Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030

February 18, 2026

Sobi to host a Capital Markets Day on 18 February 2026

February 11, 2026

Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout

February 9, 2026

Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress

February 5, 2026

Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026

February 3, 2026

Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

January 16, 2026

Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlook

January 15, 2026

Invitation: Sobi's Q4 and FY 2025 report

January 14, 2026

Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data

January 7, 2026

Calls in 2026

Decks in 2026